Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions

Michael C. Stauder, O. Kenneth MacDonald, Kenneth R. Olivier, Jason A. Call, Kyle Lafata, Charles S. Mayo, Robert C. Miller, Paul Brown, Heather J. Bauer, Yolanda I. Garces

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Background and purpose: Identify the incidence of early pulmonary toxicity in a cohort of patients treated with lung stereotactic body radiation therapy (SBRT) on consecutive treatment days. Material and methods: A total of 88 lesions in 84 patients were treated with SBRT in consecutive daily fractions (Fx) for medically inoperable non-small cell lung cancer or metastasis. The incidence of pneumonitis was evaluated and graded according to the NCI CTCAE v3.0. Results: With a median follow-up of 15.8 months (range 2.5-28.6), the median age at SBRT was 71.8 years (range 23.8-87.8). 47 lesions were centrally located and 41 were peripheral. Most central lesions were treated with 48 Gy in 4 Fx, and most peripheral lesions with 54 Gy in 3 Fx. The incidence of grade ≥2 pneumonitis was 12.5% in all patients treated, and 14.3% among the subset of patients treated with 54 Gy in 3 Fx. A total of two grade 3 toxicities were seen as one grade 5 toxicity in a patient treated for recurrence after pneumonectomy. Conclusions: Treating both central and peripheral lung lesions with SBRT in consecutive daily fractions in this cohort was well tolerated and did not cause excessive early pulmonary toxicity.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalRadiotherapy and Oncology
Volume99
Issue number2
DOIs
StatePublished - May 2011

Keywords

  • Lung neoplasms
  • Non-small cell lung carcinoma
  • Radiation pneumonitis
  • Radiotherapy
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions'. Together they form a unique fingerprint.

Cite this